Comparison of rituximab efficacy in treatment-naive and refractory inflammatory myopathies: experiences from a tertiary care centre.

Published in: Rheumatology (Oxford, England) (2024)

Rituximab is effective and safe across the spectrum of IIM. Early use in disease is associated with better outcomes.

Keyphrases